Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5381808 | 0.75 | DPP4 (0.43) | ALDH1A1HSD11B1DPP4SMN1; SMN2GAA | |
| SCHEMBL11376332 | 0.71 | ACHE (0.36) | DPP4KMT2AMEN1 | |
| SCHEMBL5376216 | 0.69 | NPC1 (0.52) | ALDH1A1SMN1; SMN2KMT2ANPC1RAB9A | |
| SCHEMBL5374193 | 0.68 | DPP4 (0.49) | ALDH1A1DPP4KMT2ANPC1RAB9A | |
| SCHEMBL5374190 | 0.68 | DPP4 (0.49) | ALDH1A1DPP4KMT2ANPC1RAB9A | |
| SCHEMBL5374063 | 0.68 | DPP4 (0.36) | ALDH1A1DPP4SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL10509918 | 0.64 | DPP4 (0.35) | DPP4LMNA | |
| SCHEMBL5381803 | 0.63 | RORC (0.38) | ALDH1A1 | |
| SCHEMBL10509749 | 0.62 | NPC1 (0.35) | ALDH1A1SMN1; SMN2KMT2ANPC1RAB9A | |
| SCHEMBL18179632 | 0.62 | ALDH1A1 (0.34) | ALDH1A1DPP4KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7238720-B2 | Pharmaceutical use of N-carbamoylazole derivatives | EISAI R & D MANAGEMENT CO. LTD. (JP) | 2007-07-03 | — | — | US | disclosed |
| US-7238720-B2 | Pharmaceutical use of N-carbamoylazole derivatives | EISAI R & D MANAGEMENT CO. LTD. (JP) | 2007-07-03 | — | — | US | disclosed |
| EP-1258480-B1 | Pharmaceutical use of N-Carbamoylazole derivatives | EISAI CO LTD (JP) | 2004-11-10 | — | — | EP | disclosed |
| EP-1258480-B1 | Pharmaceutical use of N-Carbamoylazole derivatives | EISAI CO LTD (JP) | 2004-11-10 | — | — | EP | disclosed |
| US-20040186153-A1 | Pharmaceutical use of N-carbamoylazole derivatives | EISAI R & D MANAGEMENT CO. LTD. (JP) | 2004-09-23 | — | — | US | disclosed |
| US-20030060494-A1 | Pharmaceutical use of N-carbamoylazole derivatives | EISAI CO., LTD. (JP) | 2003-03-27 | — | — | US | disclosed |
| EP-1258480-A1 | Pharmaceutical use of N-Carbamoylazole derivatives | Eisai Co., Ltd. (JP) | 2002-11-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186153-A1 | Pharmaceutical use of N-carbamoylazole derivatives | DPP4, DPP3, DPP7 | ALDH1A1 1026/4885HSD11B1 927/4885DPP4 1/4885 |
| US-20030060494-A1 | Pharmaceutical use of N-carbamoylazole derivatives | DPP4, DPP3, DPP7 | ALDH1A1 1026/4885HSD11B1 927/4885DPP4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.